The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...

The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...

The British government is set to explore whether Eli Lilly’s weight-loss drug could play a pivotal role in getting people ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...